This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter that integrates two critical PAD treatments into a single device. The innovative feature of the Philips catheter is that both the atherectomy and lithotripsy are laser-driven. clinical trial,” said Dr.
The Neuroguard Integrated Embolic Protection (IEP) system is an experimental treatment for carotid artery stenosis, also known as carotid arterydisease, a condition in which fatty-waxy deposits known as plaque builds up and blocks the normal flow of blood in the large arteries on either side of the neck.
The breakthrough designation, according to the Milpitas, CA-based technology company, is for an indication to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. of the U.S.
The 2017 ESC guidelines on the diagnosis and treatment of peripheralarterialdiseases, in collaboration with the European Society for Vascular Surgery (ESVS).” Journal of Vascular Surgery Cases, Innovations and Techniques, vol. Journal of Vascular Surgery, Mar. 2024, [link]. 2 Halliday, Alison, and Jeroen J.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content